Skip to main content

Table 1 Demographic and clinical characteristics of patients with and without venous thromboembolism (VTE)

From: Venous thromboembolism and persistent pulmonary hypertension in cancer patients: a cross-sectional study

  PE n = 48 VTE n = 72 No VTE n = 511 p-value*
Male:female (47.9):(52.1) (45.8):(54.2) (54.4):(45.6) 0.17a
Agex, years 71.3 ± 9.6 70.3 ± 9.8 68.1 ± 11.2 0.11b
Active malignant disease 20/48 (41.7) 30/72 (41.7) 192/511 (37.6) 0.50a
Heart disease 25/48 (52.1) 35/72 (48.6) 197/511 (38.6) 0.10a
 Impaired left ventricular systolic function 3/48 (6.3) 4/72 (5.6) 31/511 (6.1) 1.00c
 Atrial fibrillation 5/48 (10.4) 8/72 (11.1) 83/511 (16.2) 0.26a
 Significant aortic or mitral valve disease 5/48 (10.4) 6/72 (8.3) 40/511 (7.8) 0.88a
 Left ventricular hypertrophy 7/48 (14.6) 14/72 (19.4) 76/511 (14.9) 0.31a
No: mild to moderate: moderately severe: ≥ severe airway obstruction (63.0):(21.7):(10.9):(4.4) (70.0):(18.6):(8.6):(2.9) (62.5):(13.8):(13.0):(10.7) 0.10a
Pulmonary hypertension 16/48 (33.3) 19/72 (26.4) 71/511 (13.9) <0.01a
  1. *VTE versus No VTE subgroup
  2. Figures in parenthesis are percentages; xmean ± standard deviation; aχ2-Test; bt-test; cFisher’s exact test
  3. Active malignant disease at the time of referral: residual tumor or time interval between surgery/end of chemotherapy/radiotherapy and referral <3 months